Fulcrum Therapeutics (FULC) Change in Account Payables (2019 - 2026)

Fulcrum Therapeutics (FULC) has disclosed Change in Account Payables for 7 consecutive years, with -$1.1 million as the latest value for Q4 2025.

  • Quarterly Change in Account Payables rose 59.03% to -$1.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $428000.0 through Dec 2025, up 126.87% year-over-year, with the annual reading at $428000.0 for FY2025, 126.87% up from the prior year.
  • Change in Account Payables for Q4 2025 was -$1.1 million at Fulcrum Therapeutics, down from $946000.0 in the prior quarter.
  • The five-year high for Change in Account Payables was $1.2 million in Q4 2021, with the low at -$2.7 million in Q4 2024.
  • Average Change in Account Payables over 5 years is -$111050.0, with a median of $125500.0 recorded in 2023.
  • The sharpest move saw Change in Account Payables crashed 4357.14% in 2021, then soared 1150.0% in 2024.
  • Over 5 years, Change in Account Payables stood at $1.2 million in 2021, then dropped by 23.21% to $903000.0 in 2022, then tumbled by 190.48% to -$817000.0 in 2023, then crashed by 230.11% to -$2.7 million in 2024, then soared by 59.03% to -$1.1 million in 2025.
  • According to Business Quant data, Change in Account Payables over the past three periods came in at -$1.1 million, $946000.0, and $244000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.